Navigation Links
Anesiva Announces First Quarter 2008 Financial Results
Date:5/8/2008

opedic surgery patients is pain following the procedure even when treated with opioids. In fact, the second and third most common complaints are the nausea and vomiting caused by the very opioids taken to manage pain. Adlea addresses the need for improved post-surgical pain management by providing a locally administered alternative without the side effects of systemic opioids and other standard pain medications. There are approximately 4.5 million orthopedic surgeries and arthroscopic procedures each year in the U.S., according to the American Academy of Orthopedic Surgeons.

Recent Highlights and Accomplishments

Anesiva continued its commercialization efforts for the second quarter launch of Zingo and to advance Adlea in Phase 3 trials:

Zingo

-- In preparation for the Zingo U.S. launch in June 2008, Anesiva's

hospital-based sales force expanded its efforts to educate nurses and

physicians on the importance of treating the pain associated with IV

starts and blood draws and on the features and use of Zingo for their

pediatric patients. The Anesiva sales force is working with the sales

force of co-promotion and distribution partner Sagent Pharmaceuticals,

Inc., whose efforts are targeted at the hospital pharmacists critical

to gaining inclusion on drug formularies.

-- To grow the potential Zingo market, in March Anesiva submitted a

supplemental New Drug Application (sNDA) with the U.S. Food and Drug

Administration (FDA) to expand the indication for Zingo to include the

treatment of pain associated with peripheral IV insertions and blood

draws in adults. In U.S. hospitals, there are approximately 245 million

adult peripheral venous access procedures performed annually.

-- In line with the company's goal of establishing Zingo as a global

brand, Anesiva expanded the exclusive licensing and distribution


'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical device ... financial results will be released on,Thursday, July 31, 2008. ... at 10:00 a.m. Eastern Time, July 31, 2008, to ... hosted by Steven G.,Anderson, president and CEO of CryoLife, ...
... a disease that strikes an average of 4000 Belgians ... not yet clear. But now, VIB researchers connected to ... cleavage of the Nrg-1 protein lies at the basis ... this molecular process is a first step toward improved ...
... Makes it Easy to Connect with Technology ... on Specific Chemical Reactions, PRINCETON, N.J., July ... portal for manufacturers that require service,and support in ... bio-technology products, industrial products and,higher-value chemicals. The all-new ...
Cached Biology Technology:CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2Incorrectly cleaved protein leads to schizophrenia 2Informex365.com is Launched for Manufacturers in Search of Chemical Reactions Expertise 2Informex365.com is Launched for Manufacturers in Search of Chemical Reactions Expertise 3
(Date:4/17/2014)... under clinical trials to treat tuberculosis could be the ... against various bacteria, fungal infections and parasites, yet evade ... chemists and collaborators. , Led by U. of I. ... ways the drug SQ109 attacks the tuberculosis bacterium, how ... from yeast to malaria and how targeting multiple ...
(Date:4/17/2014)... suggests that fish consumption advisories for expecting mothers ... contaminants like persistent organic pollutants (POPs). , ... including University of Toronto Scarborough PhD student Matt ... different levels of environmental contamination, a mother,s compliance ... the body influenced exposure in her children. , ...
(Date:4/17/2014)... A Kansas State University engineer has developed a ... detects improvised explosive devices. The same technique could ... the Steven M. and Kay L. Theede chair ... nuclear engineering, and his research team have created ... or in car trunks. The distance detection method ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2
... statistical pattern recognition and image processing to help ... , Under a grant funded by the ... Science Foundation, UC San Diego structural engineering professor ... imagery-based surveillance technique which uses visible and infrared ...
... medical experts in the burgeoning field of interventional ... gather in Las Vegas July 20-23 for the ... from Rush University Medical Center in Chicago will ... course of symposium. On Monday, July 21st, ...
... success when they can thrive without killing their host. ... California Institute of Technology have uncovered how one such ... from the immune system. The human immune system ... a continual dance for survival--viruses ever seek new ways ...
Cached Biology News:UC San Diego researchers could help US military thwart explosive threats 2UC San Diego researchers could help US military thwart explosive threats 3Latest advances in interventional cardiology for congenital heart disease presented 2A viral cloaking device 2A viral cloaking device 3
... Automated instrument designed to hold up to 6 ... robust and easy to use design ensures that ... regular cyclic stretching or compression. This unit allows ... the strain to produce 64 unique strain settings. ...
... Cell Lab Quantas unique combination of ... population resolution capabilities and accurate cell ... excitation wavelengths, including UV, allowing flexible ... multi-color applications typically only achievable with ...
... FC 500 Series is a ... the most advanced technologies available. ... flexible testing, powerful software and ... help researchers optimize their overall ...
... g monoclonal antibody irreversibly crosslinked to protein ... of PDH complex from heart mitochondria. Also ... mitochondria for control immunocapture. ,The pyruvate dehydrogenase ... PDH from small amounts of tissue. This ...
Biology Products: